Robert B Ford bought $2.0M of Abbott Laboratories (ABT)
Executed Jan 23, disclosed Jan 26, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 26), the stock returned +6.3% (delay-adjusted); from the execution session (Jan 23), +6.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Robert B Ford (CHAIRMAN AND CEO) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Abbott Laboratories (ABT). Across 1 priced purchase filing, the average 21-session return was +6.5% from execution and +6.3% from disclosure (delay-adjusted; derived). The largest single filing was $46.2M of ABT (398,832 sh across 2 lots, as filed), executed Aug 25.
Healthcare · Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→398,832 sh across 2 lots
Exec Aug 25
Filed Aug 27 · 5:09 PM ET ABTSALE Abbott Laboratories $37.4M
285,388 sh × $131.17
Exec Feb 5 2025
Filed Feb 7 2025 · 5:30 PM ET